- Cetuximab-Conjugates Nanoparticles for the Treatment of Triple Negative Breast CancerArianna, Bonizzi; Miriam, Colombo; Maria Antonietta, Rizzuto; Chiara, Pacini; Laura, Pandolfi; Marta, Truffi; Matteo, Monieri; Francesco, Catrambone; Luisa, Fiandra; Fabio, Corsi; Davide, Prosperi; Serena, MazzucchelliThe 4th World Congress on Recent Advances in Nanotechnology, 2019-04-14 To 2019-04-16.
- The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina studyShao, Z.; Huang, T.; Fan, Z.; Wang, Y.; Yan, X.; Yang, H.; Wang, S.; Pang, D.; Li, H.; Wang, H.; Geng, C.; Huang, L.; Siddiqui, A.; Wang, B.; Xie, B.; Sun, G.; Restuccia, E.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
- Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 studyWang, Xiaojia; Lee, Keun Seok; Zeng, Xiaohua; Sun, Tao; Im, Young-Hyuck; Li, Huiping; Wang, Kun; Li, Huiyan; Zhou, Ping; Bao, Yuanyuan; Jiang, ZefeiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Half-Chain Trastuzumab Nanoconjugates Enhance Antitumor Activity
in HER2+ breast cancer
6阅读
